Cancer care is undergoing transformation. Foundation Medicine is a world-leading molecular insights company that provides insights to physicians and their patients through comprehensive genomic profiling. Each patient’s cancer is unique; the diagnosis of specific and individualised biomarker information helps connect patients to targeted therapies, immunotherapies or clinical trials – making personalised medicine a reality.
In New Zealand, Roche’s pharmaceutical division is the licensed distributor of FoundationOne® Companion Diagnostic (F1CDx) and FoundationOne® Liquid (F1L) for patients with solid tumours and FoundationOne® Heme for patients with sarcomas or haematological cancers including leukaemia, lymphoma and myeloma, These tests offer Comprehensive Genomic Profiling services and decision support tools that may help inform cancer treatment decisions.
